DCUBATION
Financiado
Redefining the term Incubation Period using large scale digital data
Infectious diseases pose one of the greatest risks for a global catastrophe. Just like controlling the spread of wildfires, an early detection of infectious diseases is instrumental to containing outbreaks. Nearly all infections s...
Infectious diseases pose one of the greatest risks for a global catastrophe. Just like controlling the spread of wildfires, an early detection of infectious diseases is instrumental to containing outbreaks. Nearly all infections start silently, and gradually progress until clinical symptoms appear. In this silent period, the incubation period (IP), pathogens inhibit major pathways of the innate immune system, allowing an extended period of unhindered replication. The rate of replication, as well as the type and length of suppressed symptoms vary considerably between pathogens, creating a unique signature for each pathogen. Thus, improved understanding of the IP is pivotal for early detection, prevention and control of infectious diseases. Previous studies estimating IPs have used aggregated retrospective data, and are subject to the biases of patient self-reporting. I hypothesise that the actual onset of clinical symptoms occurs earlier than previously known, can be identified more accurately, and can be used in real-time for patient empowerment. Focusing on respiratory infections, my methodological approach includes: 1) real-time evaluation of the prior risk for respiratory infections by integrating transmission models with individual-level data from electronic medical records of 4.5 Million individuals, 2) identification of micro-changes in patients’ behaviour during the early phase of an infection by prospectively analysing digital sensory data from wearable devices and mobile phones of 5000 selected participants, 3) early detection of the causing pathogen validated with self-swab kits that are tested using RT-PCR. Our preliminary work that combined an analysis of EMR and transmission modelling led to a change in public health policy in Israel. The proposed study has the potential to open new research directions on the hidden side of infectious diseases and to initiate a new era of personalized medicine through dramatic changes in patient-doctor interaction.
ver más
Duración del proyecto: 57 meses
Fecha Inicio: 2021-01-13
Fecha Fin: 2025-10-31
Fecha Fin: 2025-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-01-13
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2020-STG:
ERC STARTING GRANTS
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
TEL AVIV UNIVERSITY
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
214.42K€ |
Participante